ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Feb 05, 2020 19:40 JST
Source:
Jacobson Pharma Corporation Limited
Jacobson Pharma Launches First Influenza/RSV Home Diagnostic Kit in Hong Kong and Macau
HONG KONG, Feb 05, 2020 - (ACN Newswire) - Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Group"; Stock Code: 2633), a leading company engaged in research, development, production, marketing and sale of generic drugs and branded healthcare products, announced the launch of its first home diagnostic product for influenza/RSV under the brand name of "Dr. Freeman Flu/RSV Combo" (the "Product") in Hong Kong and Macau since January 2020. The product is available in different over-the-counter channels including major healthcare chain stores and drug stores.
Jacobson launches Dr. Freeman Flu/RSV Combo as its first influenza/RSV home diagnostic kit in the markets of Hong Kong and Macau. It is designed for qualitative determination of specific types of Influenza A and B virus and respiratory syncytial virus ("RSV") with test results available in 8 minutes.
Dr. Freeman Flu/RSV Combo is a handy one-step home diagnostic test designed for qualitative determination of specific types of Influenza A and B virus and respiratory syncytial virus ("RSV") with test results available in 8 minutes. The Product marks the first among others of its home diagnostic portfolio to be launched under the branded healthcare business platform of the Group. The Group is contemplating a potential strategic spin-off of its branded healthcare business which comprises proprietary medicines, proprietary Chinese medicines and branded health and wellness products such as health supplements, personal care products and diagnostic kits.
In scientific terms, Dr. Freeman Flu/RSV Combo uses monoclonal antibodies specific to the corresponding antigens of influenza and RSV for determination of the specific types of influenza and RSV infected, apart from the indication of the presence of influenza.
Mr Derek Sum, Chairman and Chief Executive Officer of Jacobson Pharma, commented, "We are very pleased for bringing in this useful home diagnostic product for influenza /RSV to the markets in Hong Kong and Macau. As a handy, speedy and specific self-diagnostic tool for the communicable disease, we believe the Product can highly benefit the public by helping influenza/RSV infected patients to seek prompt and effective medical treatment at the onset of the illnesses, especially during the peak flu seasons.
Bearing with the commitment to fulfilling unmet healthcare needs of consumers, we will continue to enhance our portfolio with high quality, innovative and well-trusted products in the expansion of our branded healthcare business as a strategic growth platform. Our ongoing efforts are set to strengthen our long-term strategic position and thereby enhancing the shareholders' values.".
About Jacobson Pharma Corporation Limited (Stock Code: 2633)
Jacobson Pharma is a leading generic drug company in Hong Kong. The Group's proprietary brand portfolio, notably being Po Chai Pills, Ho Chai Kung Tji Thung San, Contractubex Scar Gel, Flying Eagle Wood Lok Medicated Oil, Tong Tai Chung Woodlok Oil, Doan's Ointment, Saplingtan, Shiling Oil and Col-gan Tablet have been widely recognised by the market. The Group aims at the continued strategic enrichment of both of its generic drug and branded healthcare portfolios through the addition of high value-added products. With its corporate headquarters based in Hong Kong, the Group has also established its operating subsidiaries in China, Macau, Taiwan, Singapore and Cambodia forming a regional commercial platform to tap the market potential in the Asia Pacific and Greater China region. Jacobson Pharma has been a constituent stock of MSCI Hong Kong Micro Cap Index since 1 June 2017. For more details about Jacobson Pharma, please visit the Group's website:
http://www.jacobsonpharma.com
For media enquiries, please contact:
Strategic Financial Relations Limited
Vicky Lee Tel: (852) 2864 4834 Email:
vicky.lee@sprg.com.hk
Stephanie Liu Tel: (852) 2864 4852 Email:
stephanie.liu@sprg.com.hk
Rachel Ko Tel: (852) 2864 4806 Email:
rachel.ko@sprg.com.hk
Fax: (852) 2527 1196
Source: Jacobson Pharma Corporation Limited
Sectors: Daily Finance, Daily News, Healthcare & Pharm
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
CleverTap Recognized as a 'Strong Performer' in the Cross-Channel Marketing Hubs, Q4 2024 Report
Nov 22, 2024 22:42 JST
Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Humacyte, Inc. (HUMA) - Deadline is January 17, 2025
Nov 22, 2024 11:00 JST
NaaS Q3 2024 Recap: Strategic Shifts and Tech Innovations for Growth
Nov 21, 2024 22:59 JST
Honda Unveils Demonstration Production Line for All-Solid-State Batteries Located in Sakura City, Tochigi Prefecture, Japan
Nov 21, 2024 15:35 JST
Deadline to Lead in Securities Fraud Lawsuit Against Humacyte, Inc. (HUMA) is January 17, 2025 - Contact Kaplan Fox & Kilsheimer LLP
Nov 21, 2024 09:00 JST
ALL Study Groups Using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study
Nov 20, 2024 23:05 JST
Start of Demonstration Test of Two-Phase Direct-to-Chip Cooling in the Air-Cooled Data Center
Nov 20, 2024 15:30 JST
Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan
Nov 20, 2024 11:51 JST
Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements
Nov 20, 2024 10:24 JST
Kingsoft Announces 2024 Third Quarter Results
Nov 19, 2024 18:54 JST
NTT and Olympus Joint Demonstration Shows IOWN APN's Low-latency Capability Can Be Used for Real-time Diagnosis and Treatment on a Remote Server to Realize World's First Cloud Endoscopy System
Nov 19, 2024 15:30 JST
Supercomputer Fugaku retains first place worldwide in HPCG and Graph500 rankings
Nov 19, 2024 09:02 JST
CleverTap Recognized as a Strong Performer in Cross-Channel Marketing Hubs, Q4 2024 Report
Nov 18, 2024 23:30 JST
World's First Successful Trial of Quantum Tokens Created Using Quantum Technology
Nov 18, 2024 17:29 JST
Fujitsu and SAP Fioneer enter partnership to accelerate digital transformation in the insurance industry and deliver services that contribute to customers' sustainable business
Nov 18, 2024 12:31 JST
Expanding Possibilities with the Liquid Hydrogen-Powered GR Corolla in the Season Final Round
Nov 18, 2024 09:25 JST
COP29: Indonesian Special Envoy Hashim Djojohadikusumo Announces EUR 1,2 Billion Green Funding
Nov 16, 2024 18:00 JST
Mitsubishi Shipbuilding Holds Christening and Launch Ceremony of LNG-Powered Roll-on/Roll-off Ship TRANS HARMONY EMERALD in Shimonoseki
Nov 15, 2024 18:58 JST
Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment)
Nov 15, 2024 17:33 JST
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
Nov 15, 2024 14:31 JST
More Latest Release >>
Related Release
Jacobson Pharma Announces FY2025 Interim Results
November 22 2024 10:00 JST
Jacobson Pharma Announces FY2023 Interim Results
November 25 2022 21:21 JST
Jacobson Pharma Announces FY2022 Annual Results
June 29 2022 23:20 JST
Ban Loong, Jacobson & JBM Form Joint Venture to Tap Specialty Drugs and Branded Healthcare Markets in Greater China and Asia
June 15 2022 19:56 JST
Jacobson Pharma's Chairman Uplifts Shareholding to Above 60%
March 14 2022 19:58 JST
Jacobson Pharma Announces FY2022 Interim Results
November 26 2021 19:39 JST
Jacobson Pharma Announces FY2021 Annual Results
June 29 2021 23:19 JST
JBM (Healthcare) Limited Debuts on The Main Board of SEHK
February 05 2021 16:28 JST
JBM (Healthcare) Limited to Be Spun Off from Jacobson Pharma Corporation Limited
January 25 2021 17:20 JST
Jacobson Pharma's Proposed Spin-off and Separate Listing of JBM (Healthcare) Limited on The Main Board of The Stock Exchange of Hong Kong Limited
January 15 2021 23:25 JST
More Press release >>